— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — — 整合两家公司的砹-211(At-211)资产、开发能力及供应链,打造一家全球性靶向α疗法公司 —TOKYO 东京, ,Sept. 17, 2026 2026年9月17日/PRNewswire/ -- Alpha Fusion Inc. ('Alpha Fusion'), a clinical-stage company with an advanced At-211 drug platform, and Curadh MTR /美通社/ -- Alpha Fusion Inc.(“Alpha Fusion”)是一家处于临床阶段的公司,拥有先进的At-211药物平台,以及Curadh MTR. 。Inc. ('Curadh'), a company developing next-generation radiopharmaceuticals, announced the appointment of Dr. Alison Armour as Chief Medical Officer (CMO) of Alpha Fusion. The two companies also announced that they have entered into a Letter of Intent ('LOI') to integrate their respective Astatine-211 (At-211) programs. Inc.(“Curadh”)是一家开发下一代放射性药物的公司,宣布任命艾莉森·阿莫尔博士为Alpha Fusion的首席医疗官(CMO)。两家公司还宣布,它们已签署一份意向书(“LOI”),以整合各自的砹-211(At-211)项目。This appointment, together with the planned integration, significantly strengthens Alpha Fusion's international clinical development capabilities and positions the company to lead the global development of At-211-based therapies.. 此次任命,连同计划中的整合,显著增强了Alpha Fusion的国际临床开发能力,使公司处于引领基于At-211疗法的全球开发的有利地位。Astatine radiopharmaceuticals use the radioactive halogen isotope Astatine-211 (²¹¹At) to deliver highly localized alpha-particle radiation directly to cancer cells. In June 2025, the two companies announced a strategic partnership to advance the global development of At-211-based radiopharmaceuticals. 砹放射性药物利用放射性卤素同位素砹-211(²¹¹At)将高局部化的α粒子辐射直接递送至癌细胞。2025年6月,两家公司宣布建立战略合作伙伴关系,以推进基于砹-211的放射性药物的全球开发。This announcement marks a further deepening of that collaboration.. 这一公告标志着双方合作关系的进一步深化。Through this integration, Alpha Fusion's At-211 drug discovery platform, its clinical-stage pipeline, and its know-how and capabilities across the At-211 drug supply chain will be combined with Dr. Armour's proven track record in clinical development and regulatory affairs and Curadh's radiopharmaceutical development capabilities. 通过此次整合,Alpha Fusion的At-211药物发现平台、其临床阶段管线以及其在At-211药物供应链方面的专有知识和能力,将与Armour博士在临床开发和监管事务方面经证实的卓越业绩,以及Curadh的放射性药物开发能力相结合。Together, the two companies intend to build a global development organization with strong capabilities in both the United States and Japan — believed to be the only company in the world with multiple clinical-stage pipelines in the At-211 space.. 两家公司计划共同组建一家全球性开发组织,在美国和日本均具备强大实力,据信将成为全球唯一一家在砹-211(At-211)领域拥有多个临床阶段产品管线的公司。Comments 评论Sunao Fujioka, Representative Director and CEO, Alpha Fusion, Inc. Alpha Fusion, Inc. 代表董事兼首席执行官 藤冈直夫'This announcement marks a major milestone in Alpha Fusion's growth as a global company. In collaboration with Japanese institutions and companies, we have advanced At-211 clinical trials and demonstrated that Astatine based drugs can be manufactured and delivered throughout Japan. By combining this expertise with Dr. “这一公告标志着阿尔法融合(Alpha Fusion)作为一家全球性公司发展的重要里程碑。通过与日本机构和企业的合作,我们推进了砹-211的临床试验,并证明了基于砹的药物可以在日本全国范围内生产和配送。通过将这一专业知识与博士……”Armour's track record of securing global approval for pioneering radiopharmaceuticals, we will now have an integrated framework establishing our position as the global leader in astatine drug discovery and clinical development. We look forward to working closely with the Curadh team as we jointly lead the integration of our two companies.'. 凭借Armour在推动开创性放射性药物获得全球批准方面的卓越记录,我们现在将建立一个整合框架,确立我们在砹类药物发现与临床开发领域的全球领先地位。我们期待与Curadh团队紧密合作,共同引领两家公司的整合进程。Dr. Alison Armour, Chief Medical Officer (CMO), Alpha Fusion, Inc. 艾莉森·阿莫尔博士,首席医疗官(CMO),阿尔法融合公司'At-211 holds great potential to transform the treatment paradigm for cancer. Our Alpha Fusion colleagues have overcome the distribution challenges associated with this short half-life of the isotope, building on Japan's leading edge in At-211 development, and we will use their experience in the global development of these compounds. “At-211在变革癌症治疗范式方面具有巨大潜力。我们的Alpha Fusion同事克服了与该同位素半衰期短相关的分布挑战,依托日本在At-211开发领域的领先地位,我们将利用他们在这些化合物的全球开发中的经验。”By joining Alpha Fusion as CMO I can immediately contribute to the development of At-211 products while we pioneer the integration of our companies.'. 通过加入Alpha Fusion担任首席营销官,我可以在我们开创性地推进公司整合的同时,立即为At-211产品的开发做出贡献。Glenn Kazo, Curadh's CEO Glenn Kazo,Curadh 首席执行官'This partnership is a key component of Curadh's founding mission to 'cure with radiation' and I look forward to continuing to lead the company's integration. Together with Alpha Fusion, we combine a broad range of international investors, isotope suppliers and partners that is poised to accelerate astatine products into the marketplace.'. “此次合作是Curadh‘以辐射治愈’创立使命的关键组成部分,我期待继续领导公司的整合工作。通过与Alpha Fusion携手,我们汇聚了广泛的国际投资者、同位素供应商和合作伙伴,有望加速砹类产品推向市场。”About Alison Armour 关于艾莉森·阿莫尔Dr. Alison Armour (MB., ChB., BSC., MSc., MD., FRCP., FRCR) practiced for many years in a major European oncology center. Trained in both medical and radiation oncology with a doctorate in I-131-mIBG therapy, she had a large practice and was a major contributor to clinical trials. As a member of the EORTC lung group she was involved in many aspects of lung cancer research and was regarded as a key opinion leader in her field, before joining industry in 2014.. 艾莉森·阿莫尔博士(MB., ChB., BSC., MSc., MD., FRCP., FRCR)曾在一家大型欧洲肿瘤中心执业多年。她接受过内科肿瘤学和放射肿瘤学的双重培训,并拥有I-131-mIBG治疗博士学位,临床实践规模庞大,并为临床试验做出了重要贡献。作为欧洲癌症研究与治疗组织(EORTC)肺癌组成员,她参与了肺癌研究的多个方面,被视为该领域的关键意见领袖,直至2014年加入业界。Dr. Armour has worked for AstraZeneca, GSK, Novartis, Endocyte and Halozyme. She is experienced in all stages of drug and diagnostic development and has a track record of multiple FDA and EMA approvals for new treatments for cancer. Notably she developed the first molecularly targeted EGFR RTKi which drove the introduction of precision medicine in lung cancer.. 阿莫尔博士曾在阿斯利康、葛兰素史克、诺华、Endocyte和Halozyme工作。她在药物和诊断试剂开发的各个阶段均拥有丰富经验,并有多项癌症新疗法获得美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)批准的佳绩。值得注意的是,她开发了首款分子靶向EGFR受体酪氨酸激酶抑制剂(RTKi),推动了肺癌精准医疗的引入。Dr. Armour clinically developed the first molecularly targeted radiation therapy for prostate cancer, Pluvicto® Acquired by Novartis in 2019 for 2.1B$, in August Pluvicto® cleared a key milestone on its quest to hit 5B$ in peak sales ( Armour博士在临床上开发了首款针对前列腺癌的分子靶向放射疗法Pluvicto®。该药物于2019年被诺华以21亿美元收购,今年8月,Pluvicto®在其实现峰值销售额50亿美元的目标进程中取得了一项关键里程碑进展(link 链接). )。In 2021, she founded Curadh MTR, focused on the discovery of new molecularly targeted radiation therapies (MTR) against the most common lethal cancers. Curadh is developing molecules specifically designed for MTR. She also advises many companies on their clinical radiopharmaceutical development. 2021年,她创立了Curadh MTR公司,专注于发现针对最常见致命癌症的新型分子靶向放射疗法(MTR)。Curadh正在开发专为MTR设计的分子。她还为多家公司的临床放射性药物研发提供咨询建议。About Alpha Fusion Inc. 关于阿尔法融合公司Alpha Fusion Inc. is a clinical-stage biotechnology company advancing the clinical application of targeted alpha therapy using Astatine-211 (At-211). The company is developing multiple pipelines and building an integrated domestic and international supply chain spanning cyclotron-based At-211 production, radiolabeling, GMP formulation, and transport.. Alpha Fusion Inc. 是一家处于临床阶段的生物技术公司,致力于推进基于砹-211(At-211)的靶向α疗法在临床上的应用。该公司正在开发多条产品管线,并构建一个集成的国内外供应链,涵盖基于回旋加速器的 At-211 生产、放射性标记、GMP 制剂配制以及运输等环节。https://alpha-fusion.com/ https://alpha-fusion.com/About Curadh MTR 关于 Curadh MTR. 。Inc. 股份有限公司Curadh MTR is a U.S. and UK based company developing next-generation radiopharmaceuticals through strategic partnerships and innovative drug design, with a focus on biological approaches to molecularly targeted radiation (MTR). CUR001 has achieved proof-of concept in pre-clinical testing, and a robust pipeline of additional discovery stage targets with several isotopes are in development.. Curadh MTR 是一家总部位于美国和英国的公司,通过战略合作伙伴关系和创新药物设计开发下一代放射性药物,专注于分子靶向辐射(MTR)的生物学方法。CUR001 已在临床前测试中实现概念验证,同时还有多个处于发现阶段的靶点以及多种同位素正在开发中,形成了强大的产品管线。https://curadhmtr.com/ https://curadhmtr.com/SOURCE Alpha Fusion Inc 来源:Alpha Fusion Inc21 二十一% %more press release views with 更多新闻稿浏览量,借助Request a Demo 申请演示